Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 261-270 of 639 results
Journal of Nanobiotechnology, 2025 • January 1, 2025
The study presents LNT M2/PTX-NPs@Gel as an effective treatment for SCI, demonstrating significant improvements in neurological function recovery. The treatment modulates the inflammatory microenviron...
KEY FINDING: LNT M2/PTX-NPs@Gel treatment significantly improved motor function recovery in SCI rats, as evidenced by increased BBB scores and MEP amplitudes.
Neurosurgery Practice, 2024 • June 27, 2024
This article reviews what neurosurgeons need to know about the perioperative management of GLP-1 RAs. It discusses existing literature in clinical and preclinical studies for potential indications and...
KEY FINDING: GLP-1 RAs require tailored management for surgical patients, according to recent guidance from the American Society of Anesthesiologists.
Cureus, 2025 • February 6, 2025
SCS has emerged as a groundbreaking therapeutic modality for promoting neurological recovery in SCI by targeting residual neural pathways and enhancing neuroplasticity, offering renewed hope for indiv...
KEY FINDING: SCS activates large-to-medium afferent fibers, enhancing the interneural connections between sensory afferents and motoneurons. This strengthens monosynaptic reflex activation onto motoneurons that control agonist muscles.
Spinal Cord Series and Cases, 2025 • February 21, 2025
Individuals with SCI experience alterations in metabolism that result in increased central obesity, insulin resistance, and dyslipidemia placing them at elevated risk for developing cardiometabolic di...
KEY FINDING: The patient lost 31 pounds after 3 months of tirzepatide treatment and saw improvements in his lipid profile.
The Journal of Spinal Cord Medicine, 2022 • April 1, 2022
Chronic pain after spinal cord injury significantly affects quality of life, necessitating a shift towards non-opioid treatments due to the opioid crisis. The review highlights antiepileptic and antid...
KEY FINDING: Antiepileptic drugs like pregabalin and gabapentin have demonstrated efficacy in managing chronic SCI-related neuropathic pain.
The Journal of Spinal Cord Medicine, 2021 • September 1, 2021
This single-blind randomized controlled trial compared the effectiveness and safety of trigonal versus nontrigonal BTX-A injections in SCI patients with urinary incontinence and poor bladder complianc...
KEY FINDING: Trigonal BTX-A injection is more effective and safer than nontrigonal BTX-A injection for SCI patients with UI secondary to neurogenic-poor BC and does not result in VUR.
The Journal of Spinal Cord Medicine, 2022 • January 1, 2022
The study investigated the association between ibuprofen use and systemic inflammation markers (CRP and IL-6) in individuals with chronic SCI. Results indicated that ibuprofen use was associated with ...
KEY FINDING: Ibuprofen users had significantly lower CRP levels (2.3 mg/L versus 3.5 mg/L, P = 0.04) compared to nonusers after adjusting for clinical and demographic factors.
The Journal of Spinal Cord Medicine, 2022 • January 1, 2022
This scoping review examined the existing research on the effect of cannabis on pain intensity in individuals with spinal cord injury (SCI). The review found that the current evidence is insufficient ...
KEY FINDING: The review identified six articles covering five treatment studies, but the findings were mixed due to variations in methodology.
The Journal of Spinal Cord Medicine, 2023 • January 1, 2023
This study aimed to identify polypharmacy rates, risk factors, and commonly prescribed medications among individuals with SCI to inform medication management practices. The study found that 45% of ind...
KEY FINDING: The most commonly treated conditions among SCI patients were pain (56.5%), muscle spasms (54%), and urinary tract infections (43%).
Nutrients, 2021 • June 11, 2021
This systematic review assessed the literature on dietary supplements for sport performance in para-athletes, identifying 15 relevant studies. The review found that evidence supporting supplement use ...
KEY FINDING: Evidence for the effectiveness of supplements like caffeine, creatine, and vitamin D in para-athletes is inconclusive, with results varying across studies.